18% of patients experienced Grade 3 or higher CRS and 37% experienced Grade 3 or higher neurologic events in the primary analysis

  • Most CRS or neurologic events occurred early1

Most CRS and neurologic events in ZUMA-2 occurred early, were generally reversible, and were managed medically per established guidance1,5


Recommended monitoring1,6

Day 0 to Day 7

Doctor reviewing patient information while patient lies in hospital bed.

On-site monitoring1

Patient monitored at ATC for signs and symptoms of CRS, neurologic events, and other adverse reactions

Day 8 to Day 28

Doctor taking notes on a clipboard while speaking with patient.

Post-discharge monitoring1

Patients instructed to remain within proximity of the ATC

After treatment

 
Doctor conducting patient follow-up.

Follow-up with primary Hem/Onc7

Patient returns to referring office for routine monitoring

  • In the ZUMA-2 trial, patients with Grade >1 treatment-related CRS or neurologic events were to remain hospitalized until the adverse
    reaction resolved6

Guidance for monitoring and management of CAR T-related adverse reactions (CRS and neurologic events)1

Prescription bottles icon. Prescription bottles icon.

Ensure that 2 doses of tocilizumab are available for each patient prior to infusion. For more information on CRS and neurologic events management, please see the full Prescribing Information for TECARTUS

Phone icon. Phone icon.

Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic events occur at any time

Monitor patients daily for at least 7 days and 4 weeks postinfusion at the ATC for signs and symptoms of CRS and neurologic events. Please see the full Prescribing Information for TECARTUS for detailed adverse event management guidelines.

ATCs must ensure that healthcare providers who prescribe, dispense, or administer
TECARTUS are trained in the management of CRS and neurologic toxicities1

ATC=Authorized Treatment Center; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; Hem/Onc=hematologist/oncologist; MCL=mantle cell lymphoma; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Data on file. Kite Pharma, Inc; 2023. 3. Data on file. Kite Pharma, Inc; 2021. 4. Data on file. Kite Pharma, Inc; 2022. 5. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. 6. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma – study protocol. N Engl J Med. 2020;1-47. 7. Beaupierre A, Kahle N, Lundberg R, Patterson A. Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy. J Adv Pract Oncol. 2019;10(suppl 3):29-40.